|
1
|
Shibuya T, Watanabe K, Yamashita H,
Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H,
Shimosegawa T, et al: Isolation and characterization of vasohibin-2
as a homologue of VEGF-inducible endothelium-derived angiogenesis
inhibitor vasohibin. Arterioscler Thromb Vasc Biol. 26:1051–1057.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki Y, Kobayashi M, Miyashita H, Ohta
H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding
protein (SVBP) and its role in vasohibin secretion. J Cell Sci.
123:3094–3101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato Y: The vasohibin family: A novel
family for angiogenesis regulation. J Biochem. 153:5–11. 2013.
View Article : Google Scholar
|
|
4
|
Xue X, Gao W, Sun B, Xu Y, Han B, Wang F,
Zhang Y, Sun J, Wei J, Lu Z, et al: Vasohibin 2 is
transcriptionally activated and promotes angiogenesis in
hepatocellular carcinoma. Oncogene. 32:1724–1734. 2013. View Article : Google Scholar
|
|
5
|
Takahashi Y, Koyanagi T, Suzuki Y, Saga Y,
Kanomata N, Moriya T, Suzuki M and Sato Y: Vasohibin-2 expressed in
human serous ovarian adenocarcinoma accelerates tumor growth by
promoting angiogenesis. Mol Cancer Res. 10:1135–1146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koyanagi T, Saga Y, Takahashi Y, Suzuki Y,
Suzuki M and Sato Y: Downregulation of vasohibin-2, a novel
angiogenesis regulator, suppresses tumor growth by inhibiting
angiogenesis in endometrial cancer cells. Oncol Lett. 5:1058–1062.
2013.PubMed/NCBI
|
|
7
|
Tu M, Liu X, Han B, Ge Q, Li Z, Lu Z, Wei
J, Song G, Cai B, Lv N, et al: Vasohibin-2 promotes proliferation
in human breast cancer cells via upregulation of fibroblast growth
factor-2 and growth/differentiation factor-15 expression. Mol Med
Rep. 10:663–669. 2014.PubMed/NCBI
|
|
8
|
Li Z, Tu M, Han B, Gu Y, Xue X, Sun J, Ge
Q, Miao Y, Qian Z and Gao W: Vasohibin 2 decreases the cisplatin
sensitivity of hepatocarcinoma cell line by downregulating p53.
PLoS One. 9:e903582014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koyanagi T, Suzuki Y, Saga Y, Machida S,
Takei Y, Fujiwara H, Suzuki M and Sato Y: In vivo delivery of siRNA
targeting vasohibin-2 decreases tumor angiogenesis and suppresses
tumor growth in ovarian cancer. Cancer Sci. 104:1705–1710. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun J, Tu M, Han B, Xue X, Zhang Y, Wei J,
Chen J, Lu Z, An Y, Cai B, et al: Generation and characterization
of rabbit polyclonal antibodies against Vasohibin-2 for
determination of its intracellular localization. Int J Oncol.
43:255–261. 2013.PubMed/NCBI
|
|
11
|
Tang S, Wang Y, Zhang D, Gao Y, Ma Y, Yin
B, Sun J, Liu J and Zhang Y: Reprogramming donor cells with oocyte
extracts improves in vitro development of nuclear transfer embryos.
Anim Reprod Sci. 115:1–9. 2009. View Article : Google Scholar
|
|
12
|
Lin J, Lin X, Yang GH, Wang Y, Peng BW and
Lin JY: Toxoplasma gondii: Expression of GRA1 gene in endoplasmic
reticulum promotes both growth and adherence and modulates
intracellular calcium release in macrophages. Exp Parasitol.
125:165–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dolbeare F: Bromodeoxyuridine: A
diagnostic tool in biology and medicine, part III. proliferation in
normal, injured and diseased tissue, growth factors,
differentiation, DNA replication sites and in situ hybridization.
Histochem J. 28:531–575. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Danova M, Riccardi A and Mazzini G: Cell
cycle-related proteins and flow cytometry. Haematologica.
75:252–264. 1990.PubMed/NCBI
|
|
15
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen SM, Ohnishi T, Clark NM, He J and
Arnold LL: Investigations of rodent urinary bladder carcinogens:
Collection, processing, and evaluation of urine and bladders.
Toxicol Pathol. 35:337–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dwivedi N, Chandra S, Kashyap B, Raj V and
Agarwal A: Suprabasal expression of Ki-67 as a marker for the
severity of oral epithelial dysplasia and oral squamous cell
carcinoma. Contemp Clin Dent. 4:7–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kramer E, Herman O, Frand J, Leibou L,
Schreiber L and Vaknine H: Ki67 as a biologic marker of basal cell
carcinoma: A retrospective study. Isr Med Assoc J. 16:229–232.
2014.PubMed/NCBI
|
|
19
|
Luo Y, Kleiboeker S, Deng X and Qiu J:
Human parvovirus B19 infection causes cell cycle arrest of human
erythroid progenitors at late S phase that favors viral DNA
replication. J Virol. 87:12766–12775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robertson DS: The development of tumor
cell characteristics. J Cell Physiol. 229:705–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao P, Fu JL, Yao BY, Jia YR and Zhou ZC:
S phase cell percentage normalized BrdU incorporation rate, a new
parameter for determining S arrest. Biomed Environ Sci. 27:215–219.
2014.PubMed/NCBI
|
|
22
|
Bahrami F, Morris DL, Rufener L and
Pourgholami MH: Anticancer properties of novel aminoacetonitrile
derivative monepantel (ADD 1566) in pre-clinical models of human
ovarian cancer. Am J Cancer Res. 4:545–557. 2014.PubMed/NCBI
|
